5 Healthcare Stocks on Watch; XOMA, PPHM, NYMX, TEVA, PFE

XOMA Ltd. ( NASDAQ: XOMA ) is a Berkeley, California-based biopharmaceutical company, focusing on the discovery, development and manufacturing of therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. Last month, the company announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Bechet's disease. The small cap stock of XOMA has a 52-week range of $2.24-$12.60. Year-to-date, the stock is down 34.36%. Peregrine Pharmaceuticals ( NASDAQ: PPHM ) is a Tustin, California-based clinical-stage biopharmaceutical company, engaged in the development of monoclonal antibodies for the treatment of cancer and viral infections. Peregrine last week announced the completion of last patient in Phase 2 Coatra® brain cancer trial. Since the announcement, the small cap stock of Peregrine is up 34.94%. Year-to-date, the stock is down 24.32%. Nymox Pharmaceutical Corporation ( NASDAQ: NYMX ) is a Canada-based biopharmaceutical company. Last week, Singular Research issued a new report on Nymox, with a Buy rating and a 12-month price target of $14.50. The research report mentioned that the announcement of marketing agreement for NX-1209 to cover Europe, Middle East, Russia and parts of Africa. The small cap stock of Nymox has a 52-week range of $2.64-$7.76. Year-to-date, the stock is up 51.32%. Teva Pharmaceutical Industries Ltd. (ADR) ( NASDAQ: TEVA ) is an Israel-based global pharmaceutical company, engaged in the development, production and marketing of generic drugs covering all treatment categories. Teva announced last week that it received a Complete Response Letter (CRL) from the U.S. FDA for its supplemental New Drug Application (NDA) for lower-volume injection of glatiramer acetate. Teva ADRs have a 52-week range of $46.99-$64.95. Year-to-date, the ADRs are down 7.99%. Pfizer Inc. ( NYSE: PFE ) is a New York City-based biopharmaceutical company. Last week, Pfizer announced the submission of supplemental applications to both the U.S. FDA and the European Medicines Agency (EMA) to expand the use of Prevnar 13® to adults 50-years of age and older. The Pfizer stock has a 52-week range of $14-$20.36. Year-to-date, the stock is down 3.74%. This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell XOMA, PPHM, NYMX, TEVA and PFE at any time after this post.
Negocioenlinea
tdp2664Penny Stock Live